Digoxin and Byetta: Dangerous Drug Products

Digoxin was developed by the company Actavis Totowa to treat arrhythmias (abnormal heat rhythm) and allegedly to prevent heart failure. In April of this year, the U.S. Food and Drug Administration issued a recall of this drug. As it turned out, the use of this product leads to a dangerous side effect known as digitalis toxicity, a process that occurs when digitalis is not excreted normally through urine and the body is overexposed to the drug. This process may be fatal to the victim, which is why this drug was recalled from the market.
We had previously written a blog about Byetta developed by Eli Lilly and Company and Amylin Pharmaceuticals, Inc. This drug is used in the treatment of Type 2 diabetes, however, reports of patients developing pancreatitis, a potentially deadly side effect, occurred late in the 2007 period and have been increasing since that time. Indeed, in the fall of this year, a lawsuit was filed in California by a plaintiff who had been hospitalized for pancreatitis.
It seem as though there are new drugs coming to market almost everyday. Television ads about drugs are omnipresent. These two drugs, two among hundreds of other drug products, help to demonstrate the dangers associated with drugs that are not carefully screened by a manufacturer before being placed into the marketplace. Consumers now, more than ever, must be made aware of the dangers associated with drug treatment. The American public clearly is using more and more drug treatment. For this reason alone, it is increasingly imperative that manufacturers provide adequate warnings to patients and their physicians of dangers known to be associated with these products. Side effects can be deadly when powerful medications are involved and the public has a right to know of these dangers.
Our firm will continue to blog about these and other dangerous drugs in the future in an effort to warn the public of the dangers associated with their use. Regrettably, litigation may be the best available tool to insure that manufacturers will provide better and more informative warnings on their products so that consumers can make educated decisions about the risks and benefits of using these products.